Summary
Anteris Technologies Global CEO Touts DurAVR Redesign, Durability Claims and TAVR Market Strategy
Anteris Technologies Global (NASDAQ: AVR) CEO and founder Wayne Paterson discussed the company's DurAVR transcatheter aortic valve replacement (TAVR) program, recent clinical visibility, and the company's approach to market development during a conversation that touched on product design, tissue science, reimbursement, and longer-term interest in heart failure care pathways. Clinical interest and a "total disease management"
Anteris Technologies Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 8 | $44 | $66.24 | $22.24 | 50.55% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 30 | $282.6 | $275.1 | -$7.5 | -2.65% |
| NA Nizar Araji National Bank Of Canada /FI/ | 15 | $141.3 | $133.65 | -$7.65 | -5.41% |
| BG Bart Gancher Intech Investment Management LLC | 17,384 | $100,570.71 | $154,891.44 | $54,320.73 | 54.01% |
 Joseph Castro Nuveen LLC | 173,158 | $961,027.35 | $1.55M | $590,468.33 | 61.44% |
Anteris Technologies Ltd. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| GI Gabie Ingoglia Cantor Fitzgerald | 18,237.67 | $171,434.12 | $171,434.12 | - | - |
Anteris Technologies Ltd. (AVR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Anteris Technologies Ltd. ever had a stock split?
Anteris Technologies Ltd. Profile
| Health Care Technology Industry | Healthcare Sector | Wayne Geoffrey Paterson CEO | NASDAQ (NMS) Exchange | 03675P102 CUSIP |
| US Country | 174 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Anteris Technologies Global Corp. is a pioneering structural heart company engaged in the discovery, development, and commercialization of innovative medical devices aimed at enhancing the quality of life for patients suffering from aortic stenosis. Established in 1999 and headquartered in Toowong, Australia, Anteris has carved a niche for itself in the cardiology sector with its focus on next-generation technologies designed to offer superior solutions for cardiac conditions.
Products and Services
- DurAVR™ transcatheter heart valve system
This leading product candidate from Anteris stands out as a revolutionary transcatheter aortic valve designed for treating aortic stenosis. What makes the DurAVR™ system unique is its novel shape, engineered to replicate the performance of a healthy human aortic valve, thereby offering patients a more natural heart function post-implantation. This system underscores Anteris's commitment to providing advanced treatment options that closely align with the body's natural anatomy.
- ADAPT® anti-calcification tissue
ADAPT® represents a groundbreaking anti-calcification treatment developed by Anteris to convert xenograft tissue into durable bioscaffolds. These bioscaffolds are designed to mimic human tissue, providing a long-lasting solution for surgical repairs across various clinical settings, including aortic valve replacement. The ADAPT® technology focuses on enhancing the longevity and performance of tissue-based implants, which is crucial for reducing the incidence of valve degeneration over time.
- ComASUR™ delivery system
The ComASUR™ delivery system is a physician-engineered solution comprising a balloon-expandable delivery mechanism inclusive of a reinforced steerable catheter. This system is meticulously designed for precise navigation through the heart's anatomy, offering controlled deflection and minimizing the risk of damage to the aorta during deployment. The ComASUR™ system exemplifies Anteris's dedication to creating delivery technologies that are not only safe and effective but also tailored to enhance procedural outcomes for patients undergoing heart valve replacement.
